Skip to main content

Table 2 Clinical characteristics of the patients in Western blot analyses

From: Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease

 

Non-smokers

Smokers

COPD st I–II

COPD st IV

p-value

Total (n)

8

9

9

6

 

Male/Female

3/4*

6/3

6/3

5/1

 

Age (years)

64 (12)

60 (7)

64 (9)

53 (6)

 

Pack years

0

36 (15)

37 (12)

32 (22)

p < 0.0001

FEV1 (l)

2.9 (1.1)

3.0 (0.6)

2.0 (0.5)

0.5 (0.2)

p < 0.0001

FEV1 (% of ref)

99 (21)

87 (15)

68 (14)

16 (7)

p < 0.0001

FEV1/FVC (%)

88 (6)

82 (11)

73 (12)

35 (12)

p < 0.0001

DCO (% of ref)

92 (20)

83 (8)

65 (14)

29 (8)

p < 0.0001

DCO/VA (% of ref)

95 (19)

88 (8)

71 (17)

38 (10)

p < 0.0001

  1. Data is shown as mean (SD), as % of reference where applicable. *One healthy organ donor, background details missing. Three patients with stage II COPD and all patients with stage IV COPD had inhaled corticosteroid (below 1 mg). None of the patients were on N-acetylcysteine or vitamins. No one had previous asbestos exposure.